Skip to main content
Evidence Snapshot

Transthyretin

CHEMBL3194 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3194
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Transthyretin as ChEMBL target CHEMBL3194, mapped to UniProt P02766. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Transthyretin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3194
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P02766
Transthyretin
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Transthyretin matters

As of 2026-09-13

Transthyretin is reviewed as Transthyretin (UniProt P02766); Transthyretin shows approved-linked disease relevance led by amyloidosis. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 30 approved drugs, 1125 compounds, and 406 assays, with lead potency reaching pChEMBL 9.7.

Disease context
amyloidosis

Transthyretin shows approved-linked disease relevance led by amyloidosis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACORAMIDIS, ACORAMIDIS HYDROCHLORIDE, TAFAMIDIS.

Start review with amyloidosis because it currently carries approved-linked support. Linked drugs include ACORAMIDIS, ACORAMIDIS HYDROCHLORIDE, TAFAMIDIS, TAFAMIDIS MEGLUMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 30 approved drugs, 1125 compounds, and 406 assays for this target. The dominant activity type is IC50. CHEMBL438498 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL438498 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine
30 approved pChEMBL 9.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Transthyretin matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P02766, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why amyloidosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1125
Total Compounds
406
Total Assays
30
Approved Drugs
IC50: 346.0, KI: 12.0, EC50: 82.0, KD: 155.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL438498
 9.7 Kd —
No preferred name
CHEMBL240806
 9.5 Kd —
No preferred name
CHEMBL2103837
 8.6 EC50 Approved
No preferred name
CHEMBL2103837
 8.5 Kd Approved
No preferred name
CHEMBL3959466
 8.5 Kd —

Approved Drugs

Structure Compound First Approval
ACORAMIDIS
CHEMBL3940890
 2024
TAFAMIDIS
CHEMBL2103837
 2011
TOLCAPONE
CHEMBL1324
 1997
DICLOFENAC
CHEMBL139
 1988
DIFLUNISAL
CHEMBL898
 1982
GEMFIBROZIL
CHEMBL457
 1981
MECLOFENAMIC ACID
CHEMBL509
 1980
BITHIONOL
CHEMBL290106
 —
BENZIODARONE
CHEMBL232201
 —
BENZBROMARONE
CHEMBL388590
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3194